https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2020-03-25 11:10:502020-05-12 16:40:50Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2019-09-23 12:31:552019-10-11 15:44:33Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2018-11-20 12:03:042019-09-27 14:21:33Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2017-03-22 11:58:412019-09-27 14:21:543B Pharmaceuticals and Sovicell introduce a novel service offering for plasma protein binding analysis
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2016-11-08 14:44:312019-07-26 16:12:50KNAUER and 3B Pharmaceuticals showcase novel affinity purification process for camelid antibodies
https://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.png00imkenhttps://3b-pharma.com/wp/wp-content/uploads/2019/07/logo-1.pngimken2016-02-17 17:02:412019-07-26 12:28:00Ipsen enters into a licensing agreement with 3B Pharmaceuticals to develop novel radiopharmaceuticals in oncology
